Efficacy assessment of meloxicam, a preferential cyclooxygenase-2 inhibitor, in acute coronary syndromes without ST-segment elevation: The nonsteroidal anti-inflammatory drugs in unstable angina treatment-2 (NUT-2) pilot study

Circulation

Volumn 106, Issue 2, 2002, Pages 191-195

  Altman, Raul ^a   Luciardi, Hector Ł ^a   Muntaner, Juan ^a   Del Rio, Fatima ^a   Berman, Sofia G ^a   Lopez, Ruben ^a   Gonzalez, Claudio ^a  

^a Centro de Trombosis Buenos Aires   (Argentina)

Author keywords

Aspirin; Coronary disease; Inflammation; Thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CYCLOOXYGENASE 2 INHIBITOR; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; MELOXICAM; NADROPARIN; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG EFFICACY; ENDOTHELIUM CELL; ENZYME INHIBITION; EXTRACELLULAR MATRIX; FEMALE; HEART MUSCLE ISCHEMIA; HEART MUSCLE REVASCULARIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDIATOR RELEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE BLIND PROCEDURE; ST SEGMENT ELEVATION; THROMBOGENESIS; UNSTABLE ANGINA PECTORIS;

ACUTE DISEASE; ADULT; AGED; ANGINA, UNSTABLE; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; CORONARY DISEASE; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DRUG THERAPY, COMBINATION; ELECTROCARDIOGRAPHY; ENDPOINT DETERMINATION; FEMALE; FIBRINOLYTIC AGENTS; FOLLOW-UP STUDIES; HEPARIN; HUMANS; ISOENZYMES; MALE; MEMBRANE PROTEINS; MIDDLE AGED; PILOT PROJECTS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; SYNDROME; THIAZINES; THIAZOLES; TREATMENT OUTCOME;

EID: 0037047119     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000021599.56755.A1     Document Type: Article

References (33)

1. Inflammatory status as a main determinant of outcome in patients with unstable angina, independent of coagulation activation and endothelial cell function
2. Atherosclerosis: An inflammatory disease
3. The inflammatory etiology of unstable angina
4. Transient intermittent lymphocyte activation is responsible for the instability of angina
5. Pathophysiological basis of unstable coronary syndrome
6. Macrophages and atherosclerotic plaque stability
7. The role of plaque fissures in unstable angina: Fact or fiction?
8. Plasmin and matrix metalloproteinases in vascular remodeling
9. Membrane type matrix metalloproteinase expression in human atherosclerotic plaques: Evidence for activation by pro-inflammatory mediators
10. Inflammation, atherosclerosis, and ischemic events: Exploring the hidden side of the moon
11. Elevated levels of interleukin-6 in unstable angina
12. COX-1, COX-2, and COX-3 and the future treatment of chronic inflammatory disease
13. Anti-inflammatory, analgesic, antipyretic and related properties of meloxicam, a new non-steroidal antiinflammatory agent with favorable gastrointestinal tolerance
14. Evaluation of pharmacological profile of meloxicam as an anti-inflammatory agent, with particular reference to its relative selectivity for cyclooxygenase-2 over cyclooxygenase-1
15. Meloxicam: Influence on arachidonic acid metabolism, part II: In vivo findings
16. Nonsteroidal anti-inflammatory drugs after acute myocardial infarction
17. A randomized placebo-controlled trial to assess the efficacy of anti-inflammatory therapy with methylprednisolone in unstable angina (MUNA trial)
18. Pharmacological, pharmacokinetic and clinical profile of meloxicam
19. Thrombosis in patients with connective tissue diseases treated with specific cyclooxygenase 2 inhibitors: A report of four cases
20. Effects of selective cyclooxygenase-2 inhibition on vascular responses and thrombosis in canine coronary arteries
21. Risk of cardiovascular events associated with selective COX-2 inhibitors
22. Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib
23. Cyclo-oxygenase inhibition and thrombogenicity
24. Interaction of meloxicam with cimetidine, maalox, or aspirin
25. Meloxicam inhibits the growth of non-small cell lung cancer
26. Meloxicam effect on leukocyte migration under shear stress: A new perfused triple chamber (Hofbauer chamber) assay simulating an in vitro vascular wall
27. Secondary prevention for ischemic heart disease: Relative numbers needed to treat with different therapies
28. Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia
29. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease
30. Low molecular weight heparin in acute coronary syndrome: Evidence for superior or equivalent efficacy compared with unfractionated heparin?
31. Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin with 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-Q wave myocardial infarction: FRAX I. S. (FRAXiparine in Ischaemic Syndrome)
32. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation
33. Synthetic inhibitors of platelet glycoprotein IIb/IIIa in clinical development